Jump Financial LLC Has $10.74 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Jump Financial LLC raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 128.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 487,103 shares of the company's stock after purchasing an additional 273,493 shares during the quarter. Jump Financial LLC's holdings in Teva Pharmaceutical Industries were worth $10,736,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the company. FMR LLC raised its holdings in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its stake in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares during the period. Lingotto Investment Management LLP grew its stake in shares of Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after buying an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after purchasing an additional 569,412 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after purchasing an additional 489,041 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Up 1.3 %

NYSE TEVA traded up $0.18 during mid-day trading on Friday, hitting $13.61. The company's stock had a trading volume of 8,836,138 shares, compared to its average volume of 9,899,841. The stock's fifty day simple moving average is $15.51 and its two-hundred day simple moving average is $17.70. The firm has a market capitalization of $15.43 billion, a P/E ratio of -9.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TEVA. Bank of America dropped their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.